• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Reckson Associates Realty

Reckson Associates Realty

Western Asset Massachusetts Muni I LHMIX 4 Star

Last Price$12.77Day Change (%)0.00%
Open Price$12.77Day Change ($)0.00
Day Range12.77–12.7752-Week Range12.41–13.47

As of Wed 06/21/2017 | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. IdenTrust Achieves Direct Trusted Agent Accreditation Program from EHNAC and DirectTrust

    IdenTrust Achieves Direct Trusted Agent Accreditation Program from EHNAC and DirectTrust

  2. Tally Automates Credit Card Management to Replace Consumer Stress with Confidence

    Tally Automates Credit Card Management to Replace Consumer Stress with Confidence

  3. Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth - Research and Markets

    Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth - Research and Markets

  4. Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

    Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

  5. These refugees graduate college at a higher rate than American-born students

    These refugees graduate college at a higher rate than American-born students

  6. Norsk Titanium Announces Strategic Investment from an Affiliate of Fortress Investment Group

    Norsk Titanium Announces Strategic Investment from an Affiliate of Fortress Investment Group

  7. One Day Seminar: Effective Responses to FDA-483 Forms and Warning Letters on Quality Systems (Boston, MA, United States - November 8, 2017) - Research and Markets

    One Day Seminar: Effective Responses to FDA-483 Forms and Warning Letters on Quality Systems (Boston, MA, United States - November 8, 2017) - Research and Markets

  8. Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular ...

    Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

  9. MiX Telematics Announces Financial Results for Fourth Quarter and Full Fiscal Year 2017

    MiX Telematics Announces Financial Results for Fourth Quarter and Full Fiscal Year 2017

  10. Global Schizophrenia Therapeutics Report 2017 - Pipeline Review of 73 Companies & Drug Profiles - Research and Markets

    Global Schizophrenia Therapeutics Report 2017 - Pipeline Review of 73 Companies & Drug Profiles - Research and Markets

123

©2017 Morningstar Advisor. All right reserved.